Management of ASCVD Risk

Risk Stratification and Treatment

The American College of Cardiology recommends initiating moderate-intensity statin therapy immediately, with consideration for high-intensity statin therapy given the presence of multiple risk factors, for a patient with a 10-year ASCVD risk of 5.7% 1, 2
Patients with borderline to intermediate risk, such as a 10-year ASCVD risk of 5.7%, and multiple risk-enhancing factors, including low HDL cholesterol and elevated triglycerides, should receive more aggressive therapy 1, 2
The American College of Cardiology guidelines suggest that adults aged 40-75 years with LDL-C ≥70 mg/dL and 10-year ASCVD risk ≥7.5% should receive moderate- to high-intensity statin therapy, but the presence of risk enhancers can justify statin initiation at lower risk levels 1, 2

The American College of Cardiology recommends emphasizing heart-healthy lifestyle as foundational therapy, including dietary modifications to reduce saturated fat intake and increase fiber consumption, weight loss if overweight or obese, alcohol restriction, and regular physical activity 1, 2, 4, 5
Lifestyle interventions, such as weight loss, alcohol restriction, and carbohydrate reduction, are critical for managing hypertriglyceridemia 4, 5

The American College of Cardiology suggests that statin therapy will provide dual benefit by reducing triglycerides and LDL-C, and that lifestyle interventions are critical for triglyceride management 4, 5
Prescription omega-3 fatty acids may be considered if triglycerides remain ≥150 mg/dL after statin therapy and lifestyle modification 4

Low HDL-C is a significant independent risk factor, and lifestyle modifications, such as exercise, weight loss, and smoking cessation, can modestly improve HDL-C 1, 2
There is no specific pharmacologic therapy recommended solely for raising HDL-C, as trials have not shown benefit 5

The American College of Cardiology recommends reassessing lipid panel in 4-12 weeks after statin initiation, with a target LDL-C reduction of ≥30-50% from baseline 1, 2
Statin-related adverse effects, such as unexplained muscle pain, tenderness, or weakness, should be monitored, and patients should be educated to report these symptoms 1